Research programme: dyslipidaemia oral therapeutics - Cerenis Therapeutics

Next Previous
Drug Profile

Research programme: dyslipidaemia oral therapeutics - Cerenis Therapeutics

Alternative Names: HDL receptor enhancer

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cerenis Therapeutics
  • Class Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; GPR109A receptor agonists; GPR109B receptor agonists; HMG-CoA reductase inhibitors; Lipoprotein receptor agonists; Nitric oxide stimulants; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Dyslipidaemias

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Dyslipidaemias in Unknown (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top